0002108983-26-000001.txt : 20260203 0002108983-26-000001.hdr.sgml : 20260203 20260203124904 ACCESSION NUMBER: 0002108983-26-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260203 DATE AS OF CHANGE: 20260203 EFFECTIVENESS DATE: 20260203 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Caradon Therapeutics, Inc. CENTRAL INDEX KEY: 0002108983 ORGANIZATION NAME: EIN: 934206666 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-572221 FILM NUMBER: 26591376 BUSINESS ADDRESS: STREET 1: 1281 HYMETTUS AVE. CITY: ENCINITAS STATE: CA ZIP: 92024 BUSINESS PHONE: (619) 990-0290 MAIL ADDRESS: STREET 1: 1281 HYMETTUS AVE. CITY: ENCINITAS STATE: CA ZIP: 92024 D 1 primary_doc.xml X0708 D LIVE 0002108983 Caradon Therapeutics, Inc. 1281 HYMETTUS AVE. ENCINITAS CA CALIFORNIA 92024 (619) 990-0290 DELAWARE None None Corporation true 2023 Brian Laurence Johnson 1281 Hymettus Ave Encinitas CA CALIFORNIA 92024 Executive Officer Director Biotechnology Decline to Disclose 06b false 2026-01-08 false true true false 0 900000 559328 340672 false 7 0 0 0 The gross proceeds of the offering will be used for operating expenses, working capital and other general corporate purposes. false Caradon Therapeutics, Inc. Brian Laurence Johnson Brian Laurence Johnson Chief Executive Officer 2026-02-03